Literature DB >> 32307090

Relation of Plasma Renin Activity to Subclinical Peripheral and Coronary Artery Disease (from the Multiethnic Study of Atherosclerosis).

Jonathan T Unkart1, Matthew A Allison2, Joseph A Abdelmalek3, Nancy S Jenny4, Robyn L McClelland5, Matthew Budoff6, Joachim H Ix7, Dena E Rifkin7.   

Abstract

Experimental studies support a link between activation of the renin-angiotensin-aldosterone system and cardiovascular disease (CVD). The relationship with subclinical atherosclerosis is uncertain. Among 1,699 individuals without prevalent CVD from the Multiethnic Study of Atherosclerosis, we measured plasma renin activity (PRA) and aldosterone. Using multivariable logistic regression with restricted cubic splines, we assessed continuous log-transformed PRA and aldosterone associations with the ankle-brachial index (ABI) and coronary artery calcium (CAC) scores (Agatston) with adjustment for cardiovascular disease (CVD) risk factors, kidney function, and inflammatory biomarkers. In fully adjusted models mutually adjusting for PRA and aldosterone, higher PRA was associated with an ABI <1.0 (p overall <0.001, p nonlinear = 0.02) and CAC Agatston score >300 (p overall = 0.02, p nonlinear = 0.22), while aldosterone was not associated with either outcome. For example, compared to the 10th percentile (0.16 ng/ml/hr) of PRA, the 90th percentile (2.68 ng/ml/hr) had 3.6 times (OR 3.62; 95% CI: 2.13 to 6.13) and 1.7 times higher odds (odds ratio 1.67; 95% confidence interval: 1.13 to 2.48) of ABI <1.0 and CAC >300, respectively. These associations persisted after adjustment for levels of C-reactive protein, Interleukin-6, and Tumor Necrosis Factor-alpha. There were no significant differences in these associations by race/ethnicity or antihypertensive medication status. In conclusion, in a multiethnic cohort of community-living adults without prevalent clinical CVD, PRA was associated with greater burden of subclinical peripheral artery and coronary artery disease. These findings provide additional evidence that PRA may have deleterious effects on cardiovascular health through an atherosclerotic pathway.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32307090      PMCID: PMC7261624          DOI: 10.1016/j.amjcard.2020.03.022

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis.

Authors:  Georg Nickenig; David G Harrison
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

2.  Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study.

Authors:  Subodh Verma; Milan Gupta; Daniel T Holmes; Liqin Xu; Hwee Teoh; Sunayna Gupta; Salim Yusuf; Eva M Lonn
Journal:  Eur Heart J       Date:  2011-03-17       Impact factor: 29.983

3.  Plasma renin and outcome in the community: data from PREVEND.

Authors:  Rudolf A de Boer; Nicolas F Schroten; Stephan J L Bakker; Hasan Mahmud; Mariusz K Szymanski; Pim van der Harst; Ron T Gansevoort; Dirk J van Veldhuisen; Wiek H van Gilst; Hans L Hillege
Journal:  Eur Heart J       Date:  2012-07-17       Impact factor: 29.983

4.  Laboratory methods and quality assurance in the Cardiovascular Health Study.

Authors:  M Cushman; E S Cornell; P R Howard; E G Bovill; R P Tracy
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

5.  Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Alberto Morganti; Tanja Grammer; Karin Amrein; Bernhard O Boehm; Winfried März
Journal:  Eur Heart J       Date:  2011-05-23       Impact factor: 29.983

6.  Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Andreas Meinitzer; Bernhard O Boehm; Winfried März
Journal:  Eur Heart J       Date:  2010-03-02       Impact factor: 29.983

7.  The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Michael H Criqui; Robyn L McClelland; Mary M McDermott; Matthew A Allison; Roger S Blumenthal; Victor Aboyans; Joachim H Ix; Gregory L Burke; Kaing Liu; Steven Shea
Journal:  J Am Coll Cardiol       Date:  2010-10-26       Impact factor: 24.094

Review 8.  The multiple actions of angiotensin II in atherosclerosis.

Authors:  K M Schmidt-Ott; S Kagiyama; M I Phillips
Journal:  Regul Pept       Date:  2000-09-25

Review 9.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.

Authors:  F G R Fowkes; G D Murray; I Butcher; C L Heald; R J Lee; L E Chambless; A R Folsom; A T Hirsch; M Dramaix; G deBacker; J-C Wautrecht; M Kornitzer; A B Newman; M Cushman; K Sutton-Tyrrell; F G R Fowkes; A J Lee; J F Price; R B d'Agostino; J M Murabito; P E Norman; K Jamrozik; J D Curb; K H Masaki; B L Rodríguez; J M Dekker; L M Bouter; R J Heine; G Nijpels; C D A Stehouwer; L Ferrucci; M M McDermott; H E Stoffers; J D Hooi; J A Knottnerus; M Ogren; B Hedblad; J C Witteman; M M B Breteler; M G M Hunink; A Hofman; M H Criqui; R D Langer; A Fronek; W R Hiatt; R Hamman; H E Resnick; J Guralnik; M M McDermott
Journal:  JAMA       Date:  2008-07-09       Impact factor: 56.272

10.  Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

Authors:  C G Brilla; L S Matsubara; K T Weber
Journal:  J Mol Cell Cardiol       Date:  1993-05       Impact factor: 5.000

View more
  1 in total

1.  Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans.

Authors:  Ele Ferrannini; Maria Laura Manca; Giulia Ferrannini; Felicita Andreotti; Daniele Andreini; Roberto Latini; Marco Magnoni; Stephen A Williams; Attilio Maseri; Aldo P Maggioni
Journal:  Front Cardiovasc Med       Date:  2022-02-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.